Your session is about to expire
← Back to Search
Continued Access to Ixazomib for Multiple Myeloma
Study Summary
This trial is for people who have already participated in a study on ixazomib, and it will allow them to keep taking the drug.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 45 Patients • NCT03416374Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Ixazomib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is eligibility for participation in this trial still available?
"Confirmed. According to clinicaltrials.gov, this trial is not currently seeking participants; the original posting was on December 16th 2016 and most recently updated on December 20th 2021. There are several other trials taking place at present that could use volunteers - 2564 in total!"
Are there any precedent studies that have utilized Ixazomib?
"Presently, there are 69 clinical trials focusing on the efficacy of Ixazomib with 7 in their final phase. While Cleveland, Ohio has a significant presence among them; globally speaking, 2057 sites have activated research initiatives for this medication."
In which domains is this clinical experiment being implemented?
"This medical trial is enrolling patients from Washington University School of Medicine in Saint Louis, Missouri, Appalachian Regional Healthcare in Hazard, Kentucky and Princess Margaret Cancer Centre in Toronto, Ontario as well as 6 other sites."
Is there any potential for risk associated with Ixazomib treatment?
"We rate ixazomib's safety at a 2 because this is a Phase 2 trial. While there are preliminary studies that indicate the medication's safety, efficacy data has yet to be established."
How many participants are currently being enrolled into this clinical experiment?
"At this time, no further recruitment is being done for this examination. It originally appeared on December 16th 2016 and was recently edited on December 20th 2021. If you are searching for other studies, 2495 clinical trials with lymphoma and 69 trials utilizing Ixazomib currently have open recruitment spots."
Share this study with friends
Copy Link
Messenger